Stay updated on Long-Term Follow-Up of Dupilumab Safety in Asthma Clinical Trial

Sign up to get notified when there's something new on the Long-Term Follow-Up of Dupilumab Safety in Asthma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Long-Term Follow-Up of Dupilumab Safety in Asthma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the long-term safety description of dupilumab in the treatment of participants with moderate to severe asthma who completed the TRAVERSE-LTS12551 clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:44.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    9%
    Check dated 2024-05-22T21:03:11.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:23:44.000Z thumbnail image

Stay in the know with updates to Long-Term Follow-Up of Dupilumab Safety in Asthma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Long-Term Follow-Up of Dupilumab Safety in Asthma Clinical Trial page.